Clinical TrialAug 10, 2026, 04:24 PM
Palisade Bio Advances PALI-2108 to Phase 2; Reports Q2 2026 Results
AI Summary
Palisade Bio reported its Q2 2026 financial results and announced the advancement of its lead clinical candidate, PALI-2108, into Phase 2 development for ulcerative colitis (UC) and Crohn’s disease (CD). The company expects to enroll the first patient for the Phase 2 ASCENTRA-UC trial in 2H 2026, with primary efficacy results anticipated in 2H 2027. An IND for the Phase 2 ASCENTRA-CD trial is also expected in 2H 2026. Despite an increased net loss of $10.6 million for the quarter, the company maintains a strong cash position of $125.2 million, sufficient to fund operations through key Phase 2 clinical readouts.
Key Highlights
- PALI-2108 advancing into Phase 2 development for ulcerative colitis (UC) and Crohn’s disease (CD).
- Phase 2 ASCENTRA-UC trial enrollment expected in 2H 2026; primary efficacy results in 2H 2027.
- IND for Phase 2 ASCENTRA-CD trial expected in 2H 2026; primary efficacy results in early 2028.
- Net loss for Q2 2026 was $10.6 million, compared to $2.8 million in Q2 2025.
- Research and development expenses increased to $7.4 million in Q2 2026 from $1.7 million in Q2 2025.
- General and administrative expenses rose to $4.8 million in Q2 2026 from $1.2 million in Q2 2025.
- Recognized $0.5 million in license revenue in Q2 2026.
- Cash and cash equivalents stood at $125.2 million as of June 30, 2026.
Price Impact
More from PALI